Andrew Long, Pharmd

This phase 2 study tested whether the drug omalizumab (Xolair) can make oral immunotherapy safer for people with multiple food allergies. Sixty participants aged 2 to 25 received omalizumab before gradually increasing doses of their problem foods. The goal was to see if this appr…